The Phase 2b study of CSL112 in subjects with acute myocardial infarction (AMI) is designed to evaluate the safety and tolerability of CSL112. This multicenter, randomized, double-blind, placebo-controlled trial involves multiple doses of CSL112 at different levels to assess their effects on liver and kidney function compared to a placebo. The study aims to ensure that CSL112 can be administered safely to patients who have experienced a heart attack.